United Therapeutics (UTHR) Competitors $568.43 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$568.09 -0.34 (-0.06%) As of 05/22/2026 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UTHR vs. REGN, ALNY, BIIB, INCY, and NBIXShould you buy United Therapeutics stock or one of its competitors? MarketBeat compares United Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. UTHR vs. REGNUTHR vs. ALNYUTHR vs. BIIBUTHR vs. INCYUTHR vs. NBIXHow does United Therapeutics compare to Regeneron Pharmaceuticals?United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership. Do institutionals and insiders hold more shares of UTHR or REGN? 94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, UTHR or REGN? United Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Do analysts recommend UTHR or REGN? United Therapeutics currently has a consensus target price of $619.42, suggesting a potential upside of 8.97%. Regeneron Pharmaceuticals has a consensus target price of $792.65, suggesting a potential upside of 24.07%. Given Regeneron Pharmaceuticals' higher probable upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Regeneron Pharmaceuticals 0 Sell rating(s) 10 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 2.70 Is UTHR or REGN more profitable? United Therapeutics has a net margin of 40.62% compared to Regeneron Pharmaceuticals' net margin of 29.65%. United Therapeutics' return on equity of 19.24% beat Regeneron Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.62% 19.24% 17.25% Regeneron Pharmaceuticals 29.65%13.16%10.17% Does the media prefer UTHR or REGN? In the previous week, Regeneron Pharmaceuticals had 17 more articles in the media than United Therapeutics. MarketBeat recorded 42 mentions for Regeneron Pharmaceuticals and 25 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.37 beat Regeneron Pharmaceuticals' score of 0.20 indicating that United Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Regeneron Pharmaceuticals 15 Very Positive mention(s) 7 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 2 Very Negative mention(s) Neutral Which has better earnings and valuation, UTHR or REGN? Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$3.18B7.58$1.33B$27.0920.98Regeneron Pharmaceuticals$14.92B4.53$4.50B$41.0415.57 SummaryUnited Therapeutics beats Regeneron Pharmaceuticals on 10 of the 17 factors compared between the two stocks.How does United Therapeutics compare to Alnylam Pharmaceuticals?Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability, media sentiment and valuation. Do insiders and institutionals believe in ALNY or UTHR? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend ALNY or UTHR? Alnylam Pharmaceuticals presently has a consensus target price of $463.13, indicating a potential upside of 55.70%. United Therapeutics has a consensus target price of $619.42, indicating a potential upside of 8.97%. Given Alnylam Pharmaceuticals' higher possible upside, research analysts clearly believe Alnylam Pharmaceuticals is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 2 Strong Buy rating(s) 2.85United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Which has better earnings & valuation, ALNY or UTHR? United Therapeutics has lower revenue, but higher earnings than Alnylam Pharmaceuticals. United Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$3.71B10.69$313.75M$3.6681.27United Therapeutics$3.18B7.58$1.33B$27.0920.98 Which has more risk and volatility, ALNY or UTHR? Alnylam Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Does the media prefer ALNY or UTHR? In the previous week, United Therapeutics had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 25 mentions for United Therapeutics and 22 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.24 beat United Therapeutics' score of 0.37 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 16 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is ALNY or UTHR more profitable? United Therapeutics has a net margin of 40.62% compared to Alnylam Pharmaceuticals' net margin of 11.72%. Alnylam Pharmaceuticals' return on equity of 85.76% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals11.72% 85.76% 10.32% United Therapeutics 40.62%19.24%17.25% SummaryAlnylam Pharmaceuticals and United Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.How does United Therapeutics compare to Biogen?Biogen (NASDAQ:BIIB) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation. Do analysts rate BIIB or UTHR? Biogen currently has a consensus price target of $215.62, suggesting a potential upside of 11.28%. United Therapeutics has a consensus price target of $619.42, suggesting a potential upside of 8.97%. Given Biogen's higher probable upside, research analysts clearly believe Biogen is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 1 Sell rating(s) 13 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 2.52United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Does the media prefer BIIB or UTHR? In the previous week, United Therapeutics had 3 more articles in the media than Biogen. MarketBeat recorded 25 mentions for United Therapeutics and 22 mentions for Biogen. United Therapeutics' average media sentiment score of 0.37 beat Biogen's score of 0.31 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 8 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is BIIB or UTHR more profitable? United Therapeutics has a net margin of 40.62% compared to Biogen's net margin of 13.81%. United Therapeutics' return on equity of 19.24% beat Biogen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen13.81% 12.83% 8.01% United Therapeutics 40.62%19.24%17.25% Which has more volatility & risk, BIIB or UTHR? Biogen has a beta of 0.19, suggesting that its stock price is 81% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Do institutionals & insiders hold more shares of BIIB or UTHR? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 8.6% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better earnings & valuation, BIIB or UTHR? United Therapeutics has lower revenue, but higher earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.89B2.89$1.29B$9.3220.79United Therapeutics$3.18B7.58$1.33B$27.0920.98 SummaryUnited Therapeutics beats Biogen on 13 of the 17 factors compared between the two stocks.How does United Therapeutics compare to Incyte?United Therapeutics (NASDAQ:UTHR) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Which has stronger valuation & earnings, UTHR or INCY? United Therapeutics has higher earnings, but lower revenue than Incyte. Incyte is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnited Therapeutics$3.18B7.58$1.33B$27.0920.98Incyte$5.14B3.78$1.29B$7.0813.72 Which has more volatility and risk, UTHR or INCY? United Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market. Do institutionals and insiders have more ownership in UTHR or INCY? 94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 8.6% of United Therapeutics shares are held by insiders. Comparatively, 16.2% of Incyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts rate UTHR or INCY? United Therapeutics currently has a consensus target price of $619.42, suggesting a potential upside of 8.97%. Incyte has a consensus target price of $104.00, suggesting a potential upside of 7.04%. Given United Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe United Therapeutics is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Incyte 1 Sell rating(s) 11 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.41 Does the media refer more to UTHR or INCY? In the previous week, United Therapeutics had 10 more articles in the media than Incyte. MarketBeat recorded 25 mentions for United Therapeutics and 15 mentions for Incyte. Incyte's average media sentiment score of 0.90 beat United Therapeutics' score of 0.37 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Incyte 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is UTHR or INCY more profitable? United Therapeutics has a net margin of 40.62% compared to Incyte's net margin of 26.71%. Incyte's return on equity of 26.66% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets United Therapeutics40.62% 19.24% 17.25% Incyte 26.71%26.66%19.77% SummaryUnited Therapeutics beats Incyte on 9 of the 16 factors compared between the two stocks.How does United Therapeutics compare to Neurocrine Biosciences?Neurocrine Biosciences (NASDAQ:NBIX) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends. Do institutionals & insiders believe in NBIX or UTHR? 92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, NBIX or UTHR? Neurocrine Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Does the media prefer NBIX or UTHR? In the previous week, United Therapeutics had 3 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 25 mentions for United Therapeutics and 22 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.51 beat United Therapeutics' score of 0.37 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 8 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Is NBIX or UTHR more profitable? United Therapeutics has a net margin of 40.62% compared to Neurocrine Biosciences' net margin of 21.55%. Neurocrine Biosciences' return on equity of 19.79% beat United Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neurocrine Biosciences21.55% 19.79% 13.82% United Therapeutics 40.62%19.24%17.25% Do analysts rate NBIX or UTHR? Neurocrine Biosciences currently has a consensus price target of $185.90, indicating a potential upside of 18.64%. United Therapeutics has a consensus price target of $619.42, indicating a potential upside of 8.97%. Given Neurocrine Biosciences' higher possible upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83United Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Which has stronger valuation & earnings, NBIX or UTHR? United Therapeutics has higher revenue and earnings than Neurocrine Biosciences. United Therapeutics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurocrine Biosciences$3.10B5.08$478.60M$6.4924.14United Therapeutics$3.18B7.58$1.33B$27.0920.98 SummaryUnited Therapeutics beats Neurocrine Biosciences on 11 of the 17 factors compared between the two stocks. Get United Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UTHR vs. The Competition ExportMetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.13B$3.03B$6.43B$12.32BDividend YieldN/A1.97%2.76%5.28%P/E Ratio20.9817.7921.0125.66Price / Sales7.58500.74580.1698.40Price / Cash17.2357.7443.4956.67Price / Book4.095.8610.367.14Net Income$1.33B$74.99M$3.57B$335.98M7 Day Performance0.25%2.55%6.00%3.56%1 Month Performance0.22%-3.05%3.51%2.54%1 Year Performance84.77%34.38%34.12%35.05% United Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UTHRUnited Therapeutics3.924 of 5 stars$568.43flat$619.42+9.0%+84.8%$24.13B$3.18B20.981,400Insider TradeREGNRegeneron Pharmaceuticals4.6379 of 5 stars$629.68-9.8%$800.57+27.1%+8.6%$73.82B$14.34B15.3415,410High Trading VolumeALNYAlnylam Pharmaceuticals4.7087 of 5 stars$286.27-0.2%$471.96+64.9%+2.6%$38.32B$3.71B78.222,770Positive NewsBIIBBiogen3.8278 of 5 stars$191.91-0.5%$215.62+12.4%+54.0%$28.49B$9.89B20.597,500INCYIncyte4.6233 of 5 stars$95.19-0.1%$104.26+9.5%+51.2%$19.04B$5.14B13.442,844Positive News Related Companies and Tools Related Companies REGN Alternatives ALNY Alternatives BIIB Alternatives INCY Alternatives NBIX Alternatives EXEL Alternatives IONS Alternatives MDGL Alternatives BMRN Alternatives HALO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UTHR) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
